Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer

By sjmartinez • November 20, 2024

Oh MS, Dumitras C, Salehi-Rad R, Tran LM, Krysan K, Lim RJ, Jing Z, Tappuni S, Lisberg A, Garon EB, Dubinett SM, Liu B. Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer. Mol Cancer Ther. 2024 Nov 19. doi: 10.1158/1535-7163.MCT-24-0435. Epub ahead of print. PMID: 39559833.

Tags: Fellow, Hematology/Oncology, Post Doc, Publications, Pulmonary, Critical Care & Sleep Medicine, Veterans Administration

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave[...]

Liquid Biopsy in Hepatocellular Carcinoma: Challenges, Advances, and Clinical Implications

Park J, Lee YT, Agopian VG, Liu JS, Koltsova EK, You S, Zhu Y, Tseng HR, Yang JD. Liquid Biopsy in Hepatocellular Carcinoma: Challenges, Advances,[...]

Racial/Ethnic Disparities in Oncology Clinical Trial Participation: Investigator Attitudes, Needs, and Motivation to Improve

Bransky NP, Walling AM, Klomhaus AM, Glaspy JA, Garcia-Jimenez MD. Racial/Ethnic Disparities in Oncology Clinical Trial Participation: Investigator Attitudes, Needs, and Motivation to Improve. JCO[...]